Syneos Health, Inc. (SYNH) Prices 7M Share Secondary Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Syneos Health Announces Pricing of Secondary Offering of Common Stock
May 3, 2021 9:33 PM EDTMORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the Company or Syneos Health), the only fully integrated biopharmaceutical solutions organization, today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the Selling Stockholders) of an aggregate of 7,000,000 shares of the Companys common stock (the Offering). The Selling Stockholders have also granted the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any... More
